Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression

References

• Galli F, Aguilera JV, Palermo B, Markovic SN, Nisticò P, Signore A. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res. 2020;39(1):1–14. doi:10.1186/s13046-020-01586-y.
   PubMed Web of Science ®Google Scholar
• Tcyganov E, Mastio J, Chen E, Gabrilovich DI. Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol. 2019;51:76–82. doi:10.1016/j.coi.2018.03.009.
   Web of Science ®Google Scholar
• Monteran L, Ershaid N, Doron H, Zait Y, Scharff Y, Ben-Yosef S, Avivi C, Barshack I, Sonnenblick A, Erez N. Chemotherapy-induced complement signal- ing modulates immunosuppression and metastatic relapse in breast cancer. Nat Commun. 2022;13(1). doi:10.1038/s41467-022-33598-x.
   PubMed Web of Science ®Google Scholar
• Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32(1):19–25. doi:10.1016/j.it.2010.10.002.
   PubMed Web of Science ®Google Scholar
• Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G. Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front Immunol. 2014;5(October):1–15. doi:10.3389/fimmu.2014.00489.
   PubMedGoogle Scholar
• Greten TF. Does CSF1R Blockade turn into friendly fire? Cancer Cell. 2018;32(5):546–547. doi:10.1016/j.ccell.2017.10.012.
   Web of Science ®Google Scholar
• Ma T, Renz BW, Ilmer M, Koch D, Yang Y, Werner J, Bazhin AV. Myeloid-derived suppressor cells in solid tumors. Cells. 2022;11(2):310–322. doi:10.3390/cells11020310.
   PubMed Web of Science ®Google Scholar
• Li T, Li X, Zamani A, Wang W, Lee C-N, Li M, Luo G, Eiler E, Sun H, Ghosh S, et al. C-Rel is a myeloid checkpoint for cancer immunotherapy. Nat Cancer. 2020;1(5):507–517. doi:10.1038/s43018-020-0061-3.
   PubMedGoogle Scholar
• Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, Kogadeeva M, Picotti P, Meissner F, Mann M, et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity article L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167(3):829–842.e13. doi:10.1016/j.cell.2016.09.031.
   PubMed Web of Science ®Google Scholar
• Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ B. 2022;39:147–164. doi:10.1200/EDBK_240837.
   Google Scholar
• Ries CH, Hoves S, Cannarile MA, Rüttinger D. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol. 2015;23:45–51. doi:10.1016/j.coph.2015.05.008.
   PubMed Web of Science ®Google Scholar
• Baram L, Peled E, Berman P, Yellin B, Besser E, Benami M, Louria-Hayon I, Lewitus GM, Meiri D. The heterogeneity and complexity of Cannabis extracts as antitumor agents. Oncotarget. 2019;10(41):4091–4106. doi:10.18632/oncotarget.26983.
   PubMedGoogle Scholar
• Hinz B, Ramer R. Cannabinoids as anticancer drugs: current status of preclinical research. Br J Cancer. 2022;127(1):1–13. doi:10.1038/s41416-022-01727-4.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4):692–698. doi:10.1007/s13311-015-0374-6.
   PubMed Web of Science ®Google Scholar
• Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. 2021;22(17):22. doi:10.3390/ijms22179472.
   Web of Science ®Google Scholar
• Jacobson MR, Watts JJ, Boileau I, Tong J, Mizrahi R. A systematic review of phytocannabinoid exposure on the endocannabinoid system: implications for psychosis. Eur Neuropsychopharmacol. 2019;29(3):330–348. doi:10.1016/j.euroneuro.2018.12.014.
   PubMed Web of Science ®Google Scholar
• Straiker A, Wilson S, Corey W, Dvorakova M, Bosquez T, Tracey J, Wilkowski C, Ho K, Wager-Miller J, Mackie K, et al. An evaluation of understudied phytocannabinoids and their effects in two neuronal models. Molecules. 2021;26(17):1–17. doi:10.3390/molecules26175352.
   Web of Science ®Google Scholar
• Berman P, Sulimani L, Gelfand A, Amsalem K, Lewitus GM, Meiri D. Cannabinoidomics – an analytical approach to understand the effect of medical Cannabis treatment on the endocannabinoid metabolome. Talanta. 2020;219:121336. doi:10.1016/j.talanta.2020.121336.
   PubMed Web of Science ®Google Scholar
• Chakravarti B, Ravi J, Ganju RK. Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget. 2014;5(15):5852–5872. doi:10.18632/oncotarget.2233.
   PubMedGoogle Scholar
• Zagzoog A, Mohamed KA, Kim HJJ, Kim ED, Frank CS, Black T, Jadhav PD, Holbrook LA, Laprairie RB. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep. 2020;10(1):1–13. doi:10.1038/s41598-020-77175-y.
   PubMed Web of Science ®Google Scholar
• Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS. Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid- derived suppressor cells. Front Immunol. 2018;9:1–12.
   PubMed Web of Science ®Google Scholar
• Passarelli A, Mannavola F, Stucci LS, Tucci M, Silvestris F. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017;8(62):106132–106142. doi:10.18632/oncotarget.22190.
   PubMedGoogle Scholar
• Berman P, Futoran K, Lewitus GM, Mukha D, Benami M, Shlomi T, Meiri D. A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci Rep. 2018;8(1):1–15. doi:10.1038/s41598-018-32651-4.
   PubMedGoogle Scholar
• Galve-Roperh I, Chiurchiù V, Díaz-Alonso J, Bari M, Guzmán M, Maccarrone M. Prog Lipid Res Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog Lipid Res. 2013;52(4):633–650. doi:10.1016/j.plipres.2013.05.004.
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7(1):1–10. doi:10.1038/ncomms12150.
   Google Scholar
• Clementi E, Cervia D, Di Renzo I, Moscheni C, Bassi MT, Campana L, Martelli C, Catalani E, Giovarelli M, Zecchini S, et al. Nitric oxide generated by tumor-associated macrophages is responsible for cancer resistance to cisplatin and correlated with syntaxin 4 and acid sphingomyelinase inhibition. Front Immunol. 2018;9(May). doi:10.3389/fimmu.2018.01186.
   PubMedGoogle Scholar
• Zhou Y, Yoshida S, Kubo Y, Yoshimura T, Kobayashi Y, Nakama T, Yamaguchi M, Ishikawa K, Oshima Y, Ishibashi T. Different distributions of M1 and M2 macrophages in a mouse model of laser-induced choroidal neovascularization. Mol Med Rep. 2017;15(6):3949–3956. doi:10.3892/mmr.2017.6491.
   PubMed Web of Science ®Google Scholar
• Patrinely JR, Baker LX, Davis EJ, Song H, Ye F, Johnson DB. Outcomes after progression of disease with anti – PD-1/PD-L1 therapy for patients with advanced melanoma. Cancer. 2020;126(15):3448–3455. doi:10.1002/cncr.32984.
   PubMed Web of Science ®Google Scholar
• Sockolosky JT, Dougan M, Ingram JR, Chi C, Ho M, Kauke MJ, Ploegh HL, Garcia KC. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci USA. 2016;113(19). doi:10.1073/pnas.1604268113.
   PubMed Web of Science ®Google Scholar
• Fejza A, Polano M, Camicia L, Poletto E, Carobolante G, Toffoli G, Mongiat M, Andreuzzi E. The efficacy of anti-PD-L1 treatment in melanoma is associated with the expression of the ECM molecule EMILIN2. Int J Mol Sci. 2021;22(14):7511–7515. doi:10.3390/ijms22147511.
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Ribas A. Tumor-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2021;20(1):25–39. doi:10.1038/s41577-019-0218-4.
   Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982. doi:10.1200/JCO.2014.59.4358.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Su M, Liu L, Tang Y, Pan Y, Sun J. Clinical application of cytokines in cancer immunotherapy. Drug Des Devel Ther. 2021;15:2269–2287. doi:10.2147/DDDT.S308578.
   PubMed Web of Science ®Google Scholar
• Yagiz K, Rittling SR. Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. Exp Cell Res. 2010;315(14):2442–2452. doi:10.1016/j.yexcr.2009.05.002.
   Web of Science ®Google Scholar
• Ding J, Guo C, Hu P, Chen J, Liu Q, Wu X, Cao Y, Wu J. CSF1 is involved in breast cancer progression through inducing monocyte differentiation and homing. Int J Oncol. 2016;49(5):2064–2074. doi:10.3892/ijo.2016.3680.
   PubMed Web of Science ®Google Scholar
• Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for Cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204–212. doi:10.1124/jpet.120.000340.
   PubMed Web of Science ®Google Scholar
• Lewis MA, Russo EB, Smith KM, Village W, Republic C, Lewis M. Pharmacological foundations of Cannabis chemovars authors. Planta Med. 2018;84(4):225–233. doi:10.1055/s-0043-122240.
   PubMed Web of Science ®Google Scholar
• Procaccia S, Lewitus GM, Lipson Feder C, Shapira A, Berman P, Meiri D. Cannabis for medical use: versatile plant rather than a single drug. Front Pharmacol. 2022;13(April):1–14. doi:10.3389/fphar.2022.894960.
   Google Scholar
• Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor miroenvironment. Trends Immunol. 2017;37(3):208–220. doi:10.1016/j.it.2016.01.004.
   Web of Science ®Google Scholar
• Youn J-I, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2012;40(11):2969–2975. doi:10.1002/eji.201040895.
   Web of Science ®Google Scholar
• Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann Ny Acad Sci. 2014;1319(1):47–65. doi:10.1111/nyas.12469.
   PubMed Web of Science ®Google Scholar
• Kienzl M, Kargl J, Schicho R. The immune endocannabinoid system of the tumor microenvironment. Int J Mol Sci. 2020;21(23):8929. doi:10.3390/ijms21238929.
   PubMed Web of Science ®Google Scholar
• Qiu C, Yang L, Wang B, Cui L, Li C, Zhuo Y, Zhang L, Zhang S, Zhang Q, Wang X. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer. Biomed Pharmacother. 2019;115(May):108952. doi:10.1016/j.biopha.2019.108952.
   PubMedGoogle Scholar
• Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar A, Shilo K, Carson WE, et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol. 2015;9(4):906–919. doi:10.1016/j.molonc.2014.12.010.
   PubMed Web of Science ®Google Scholar
• Davis MP. Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Cancer Netw. 2016;14(7):915–922. doi:10.6004/jnccn.2016.0094.
   PubMed Web of Science ®Google Scholar
• Emerson C Swallowable Cannabigerol tablets for sleep quality in veterans [Internet]. 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05088018
   Google Scholar
• Aviram J, Lewitus GM, Vysotski Y, Amna MA, Ouryvaev A, Procaccia S, Cohen I, Leibovici A, Akria L, Goncharov D, et al. The effectiveness and safety of medical Cannabis for treating cancer related symptoms in oncology patients. Front Pain Res. 2022;3(May):1–14. doi:10.3389/fpain.2022.861037.
   Google Scholar
• Xiong X, Chen S, Shen J, You H, Yang H, Yan C, Fang Z, Zhang J, Cai X, Dong X, et al. Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2. Signal Transduct Target Ther. 2022;7(1). doi:10.1038/s41392-022-00918-y.
   Web of Science ®Google Scholar
• Bar-Sela G, Cohen I, Campisi-Pinto S, Lewitus GM, Oz-Ari L, Jehassi A, Peer A, Turgeman I, Vernicova O, Berman P, et al. Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers (Basel). 2020;12(9):12. doi:10.3390/cancers12092447.
   Web of Science ®Google Scholar
• Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G. Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. Oncologist. 2019;24(4):549–554. doi:10.1634/theoncologist.2018-0383.
   PubMed Web of Science ®Google Scholar
• Hegde VL, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur J Immunol. 2010;40(12):3358–3371. doi:10.1002/eji.201040667.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang J, Hu B, Qian F. High expression of CSF-1R predicts poor prognosis and CSF-1R high tumor-associated macrophages inhibit anti-tumor immunity in colon adenocarcinoma. Front Oncol. 2022;12(April):1–13. doi:10.3389/fonc.2022.850767.
   Google Scholar
• Liu H, Zhang H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J, Sun Y. Increased expression of CSF-1 Associates with poor prognosis of patients with gastric cancer undergoing gastrectomy. Medicine (Baltimore). 2016;95(9):1–7. doi:10.1097/MD.0000000000002675.
   Web of Science ®Google Scholar